Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

FDA Approves Siltuximab for Multicentric Castleman's Disease

April 23rd 2014

The FDA has approved the anti-IL-6 chimeric monoclonal antibody siltuximab as a treatment for HIV- and HHV-8-negative patients with multicentric Castleman's disease.

Dr. Pal on Sequencing Abiraterone and Enzalutamide in mCRPC

April 23rd 2014

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses the results of a retrospective analysis of the effect of prior abiraterone use on the activity level of enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC).

Novartis Plans Acquisition of GSK's Oncology Products

April 22nd 2014

GSK and Novartis have struck a deal that will move all of GSK's oncology assets to Novartis, all of Novartis' non-flu-related vaccines to GSK, and will result in a joint consumer healthcare venture.

Greater Use of Nonphysician Providers Seen in Office Settings

April 22nd 2014

Employing nonphysician providers (NPPs) by physician practices has grown in the past 15 years

Ellen T. Matloff on Changes to the Field of Genetic Testing

April 22nd 2014

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, gives an overview of the recent changes to the field of genetic testing.

FDA Approves Ramucirumab for Gastric and GEJ Adenocarcinoma

April 21st 2014

The FDA has approved the VEGFR-2 inhibitor ramucirumab as a treatment for patients with patients with unresectable gastric cancer or gastroesophageal junction adenocarcinoma, based on a significant extension in OS.

Teaching Billing and Coding Techniques Benefit Second-Year Students

April 21st 2014

In addition to the clinical skills lectures included in medical school curriculum, second-year medical students at Rutgers New Jersey Medical School in Newark, NJ, are also receiving a course in understanding the basics of billing and coding

FDA Approves First-Line Ofatumumab for Fludarabine-Ineligible Patients With CLL

April 17th 2014

The FDA has approved ofatumumab plus chlorambucil for previously untreated patients with chronic lymphocytic leukemia who are considered inappropriate for treatment with fludarabine therapy.

Dr. Salerno on Access to Care for Breast Cancer Patients

April 17th 2014

Judith A. Salerno, MD, MS, president, CEO, Susan G. Komen, discusses access to care for patients with breast cancer.

Dr. Penson on Advantages/ Disadvantages of Large Urologic Practices

April 17th 2014

David F. Penson, MD, MPH, director, Center for Surgical Quality and Outcomes Research Professor of Urologic Surgery, Paul V. Hamilton, M.D. and Virginia E. Howd Chair in Urologic Oncology, professor of medicine, Vanderbilt University Medical Center, discusses some of the advantages and disadvantages of a large urologic practice.

Oncologist Compensation Highest in Southwest, With 23% in ACOs Already

April 16th 2014

Among physicians, oncologists fall slightly above the middle in terms of compensation, with average earnings reported at $290,000.

As CMS Contemplates ICD-10 Delay, Take Advantage of the Slow Rollout

April 15th 2014

Even as the Centers for Medicare & Medicaid Services (CMS) examines the implications of the ICD-10 delay there are some steps oncology and hematology practice managers can take now before the rollout gets into full swing.

Small Oncology Practices Can Look to SHOP Marketplace for Employee Benefit Plans

April 14th 2014

Small oncology practices employing fewer than 50 full-time employees might consider looking to the Small Business Health Options Program offered through the Affordable Care Act.

Reimbursement Models Force Oncologists to Balance Clinical and Financial Risk

April 11th 2014

I would like to begin by expressing my excitement about my new position as editor-in-chief of Oncology Business Management.

Delayed Launch of Sunshine Act Website May Affect Physician Review

April 10th 2014

A delay in the launch of the Centers for Medicare & Medicaid Services (CMS) web site that tracks the financial relationship between physician and industry may prevent physicians from fully reviewing the data.

Medicare Data Reveals Top Billing Docs

April 9th 2014

Buckling to calls for transparency and a Wall Street Journal court case requiring the agency to provide public access to physician billing records, the Centers for Medicare & Medicaid Services (CMS) released a database containing transactions worth $77 billion by 880,000 physicians and physician practices certified to collect from Medicare

MSK's CAR Trials Halted Temporarily Amid Safety Review

April 9th 2014

Five early-phase clinical trials exploring chimeric antigen receptor (CAR) T-cell therapy have been suspended temporarily in response to the deaths of 2 patients with adult B-cell acute lymphoblastic leukemia

Avoiding Meaningful Use Fee Adjustments

April 8th 2014

Community oncologists and hematologists who participate in the Medicare Electronic Health Records Incentive Program may be subject to fee adjustments from the agency beginning January 1, 2015.

Aduro BioTech Immunotherapy Duo Shows Promise in Pancreatic Cancer

April 3rd 2014

The use of immunotherapy for pancreatic cancer has had limited exposure, but Aduro BioTech, Inc, has had phase II success with an approach in which two vaccines are administered. The vaccines, GVAX Pancreas and CRS-207, are administered to patients sequentially.

The Retreatment Question: Research Suggests Benefits to Continuing Molecularly Targeted Therapy Beyond Progression

April 2nd 2014

The readministration of a cytotoxic antineoplastic agent is a well-established management paradigm in a number of malignancies, yet it is generally believed such a strategy may not prove beneficial if the patient experiences disease progression while receiving the therapy.